Notice of AGM & Annual Report & Accounts

RNS Number : 4784N

Immupharma PLC

01 June 2022

 

RNS: RELEASE  1 JUNE 2022

ImmuPharma PLC

("ImmuPharma" or the "Company")

Notice of AGM & Annual Report & Accounts

ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, confirms that the Notice of Annual General Meeting ("AGM") has been posted to shareholders. The Annual Report and Accounts for the year ended 31 December 2021 will be posted to shareholders on 6 June 2022.

These documents will be available shortly, in electronic form, for download on the Company's website www.immupharma.co.uk .

ImmuPharma's AGM will be held on Tuesday 28 June 2022 @ 10.30am (BST) at: One Bartholomew Close, London, EC1A 7BL.

Ends

For further information please contact: ImmuPharma PLC ( www.immupharma.com ) Tim McCarthy, Chairman and Chief Executive + 44 (0) 207 206 2650 Lisa Baderoon, Head of Investor Relations + 44 (0) 7721 413496 SPARK Advisory Partners Limited (NOMAD) Neil Baldwin Stanford Capital Partners (Joint Broker) Patrick Claridge, John Howes, Bob Pountney SI Capital (Joint Broker) Nick Emerson [phone] [phone] [phone]

Notes to Editors

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases, metabolic diseases, anti-infectives and cancer. The lead program, Lupuzor™, is a first-in class autophagy immunomodulator which is in Phase 3 for the treatment of lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. ImmuPharma and Avion Pharmaceuticals signed on 28 November 2019, an exclusive licence and development agreement and trademark agreement for Lupuzor™ to fund a new international Phase 3 trial for Lupuzor™ and commercialise in the US.

For additional information about ImmuPharma please visit www.immupharma.co.uk

ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895

 

END

 

 

ACSFLFLAEDILVIF